EDGAR·FLOW

SPRUCE BIOSCIENCES, INC. — Form 8-K

Filed November 9, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
Spruce Biosciences amended its Avenue Capital loan on November 6, 2026, increasing Tranche 2 availability to $15M (drawable Jan–Mar 2027) and extending the interest-only period through March 31, 2027 (potentially to October 2028). Simultaneously, Spruce separated its CRHX-101 program into a wholly-owned subsidiary, Adrenyx Biosciences, which raised $5M in secured convertible notes from an institutional investor with up to $10M available and $50M expected in a future private placement; Spruce plans to distribute all Adrenyx shares pro-rata to shareholders in H1 2027. TA-ERT BLA submission remains on track for December 2026; Q3 2026 cash was $87.7M (vs. $48.9M at year-end 2025); net loss was $24M for Q3 2026 ($52.5M for nine months).
Why this rating

Debt amendment and spin-off extend runway materially; $87.7M cash (31× market cap) and $15M new borrowing capacity are significant for a $2.8M company. BLA submission on track is de-risking. Spin reduces focus risk. Material relative to company scale.

Tradability signal
NO TRADE

No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
at our read · unknown
$41.30
+10 min · unknown
$41.01 ▼ 0.70%
+30 min · unknown
$44.00 ▲ 6.54%
+1 hr · unknown
$48.04 ▲ 16.32%
+4 hrs · unknown
$50.78 ▲ 22.95%

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ SPRB · stock on Yahoo Finance ↗

See more from November 9, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.